Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Correction to: Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma.

Masoud SJ, Perone JA, Farrow NE, Mosca PJ, Tyler DS, Beasley GM.

Curr Treat Options Oncol. 2019 Aug 29;20(10):76. doi: 10.1007/s11864-019-0674-x.

PMID:
31468223
2.

Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size.

Masoud SJ, Hu JB, Beasley GM, Stewart JH 4th, Mosca PJ.

Ann Surg Oncol. 2019 Dec;26(13):4633-4641. doi: 10.1245/s10434-019-07691-3. Epub 2019 Aug 14.

PMID:
31414290
3.

Type of Organ Transplanted Impacts the Risk and Presentation of Cutaneous Squamous Cell Carcinoma in Transplant Recipients.

Puza CJ, Beasley GM, Barbas AS, Mosca PJ.

Exp Clin Transplant. 2019 Apr 9. doi: 10.6002/ect.2018.0238. [Epub ahead of print]

4.

Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis.

Miura JT, Kroon HM, Beasley GM, Mullen D, Farrow NE, Mosca PJ, Lowe MC, Farley CR, Kim Y, Naqvi SMH, Potdar A, Daou H, Sun J, Farma JM, Henderson MA, Speakman D, Serpell J, Delman KA, Mark Smithers B, Coventry BJ, Tyler DS, Thompson JF, Zager JS.

Ann Surg Oncol. 2019 Aug;26(8):2486-2494. doi: 10.1245/s10434-019-07288-w. Epub 2019 Mar 25.

PMID:
30911949
5.

The Improvement Readiness scale of the SCORE survey: a metric to assess capacity for quality improvement in healthcare.

Adair KC, Quow K, Frankel A, Mosca PJ, Profit J, Hadley A, Leonard M, Bryan Sexton J.

BMC Health Serv Res. 2018 Dec 17;18(1):975. doi: 10.1186/s12913-018-3743-0.

6.

Updates in adjuvant systemic therapy for melanoma.

Kwak M, Farrow NE, Salama AKS, Mosca PJ, Hanks BA, Slingluff CL, Beasley GM.

J Surg Oncol. 2019 Jan;119(2):222-231. doi: 10.1002/jso.25298. Epub 2018 Nov 27. Review.

PMID:
30481375
7.

Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma.

Masoud SJ, Perone JA, Farrow NE, Mosca PJ, Tyler DS, Beasley GM.

Curr Treat Options Oncol. 2018 Sep 19;19(11):55. doi: 10.1007/s11864-018-0575-4. Review. Erratum in: Curr Treat Options Oncol. 2019 Aug 29;20(10):76.

8.

Early-stage melanoma and hematopoietic stem cell transplantation outcomes.

Puza CJ, Mosca PJ, Cardones AR.

J Am Acad Dermatol. 2019 Mar;80(3):786-788. doi: 10.1016/j.jaad.2018.07.010. Epub 2018 Jul 17. No abstract available.

PMID:
30025826
9.

The impact of transplant rejection on cutaneous squamous cell carcinoma in renal transplant recipients.

Puza CJ, Myers SA, Cardones AR, Beasley GM, Mosca PJ.

Clin Exp Dermatol. 2019 Apr;44(3):265-269. doi: 10.1111/ced.13699. Epub 2018 Jun 27.

PMID:
29952022
10.

Outcomes of patients with a pretransplant history of early-stage melanoma.

Puza CJ, Barbas AS, Mosca PJ.

Melanoma Res. 2018 Oct;28(5):471-474. doi: 10.1097/CMR.0000000000000471.

PMID:
29944608
11.

Timing and Number of Cutaneous Squamous Cell Carcinomas in Transplant Recipients.

Puza CJ, Cardones AR, Mosca PJ.

JAMA Dermatol. 2018 Jun 1;154(6):727-728. doi: 10.1001/jamadermatol.2018.0856. No abstract available.

12.

Does the number of sentinel lymph nodes removed affect the false negative rate for head and neck melanoma?

Puza CJ, Josyula S, Terando AM, Howard JH, Agnese DM, Mosca PJ, Lee WT, Beasley GM.

J Surg Oncol. 2018 Jun;117(7):1584-1588. doi: 10.1002/jso.25025. Epub 2018 Mar 7.

PMID:
29513892
13.

Examining the Incidence and Presentation of Melanoma in the Cardiothoracic Transplant Population.

Puza CJ, Cardones AR, Mosca PJ.

JAMA Dermatol. 2018 May 1;154(5):589-591. doi: 10.1001/jamadermatol.2018.0130.

14.

Correction to: The changing landscape of dermatology practice: melanoma and pump-probe laser microscopy.

Puza CJ, Warren WS, Mosca PJ.

Lasers Med Sci. 2017 Dec;32(9):2173. doi: 10.1007/s10103-017-2339-y.

PMID:
28980190
15.

The changing landscape of dermatology practice: melanoma and pump-probe laser microscopy.

Puza CJ, Warren WS, Mosca PJ.

Lasers Med Sci. 2017 Nov;32(8):1935-1939. doi: 10.1007/s10103-017-2319-2. Epub 2017 Sep 11. Review. Erratum in: Lasers Med Sci. 2017 Dec;32(9):2173. Warren WS [added].

PMID:
28890988
16.

Clinical Acuity Shorthand System: a standardized classification tool to facilitate handoffs.

Gilmore BF, Brys AK, Nath NS, Barfield M, Rialon KL, Truong T, Pomann GM, Migaly J, Mosca PJ.

J Surg Res. 2017 May 1;211:163-171. doi: 10.1016/j.jss.2016.10.033. Epub 2016 Nov 7.

PMID:
28501113
17.

Management of a cutaneous squamous cell carcinoma overlying an AV fistula.

Nath NS, Gilmore BF, McCann RK, Mosca PJ.

BMJ Case Rep. 2017 May 6;2017. pii: bcr-2016-218932. doi: 10.1136/bcr-2016-218932.

18.

Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity Sarcoma.

Mullinax JE, Kroon HM, Thompson JF, Nath N, Mosca PJ, Farma JM, Bhati R, Hardmann D, Sileno S, O'Donoghue C, Perez M, Naqvi SM, Chen YA, Gonzalez RJ, Zager JS.

J Am Coll Surg. 2017 Apr;224(4):635-642. doi: 10.1016/j.jamcollsurg.2016.12.035. Epub 2017 Feb 15.

PMID:
28214556
19.

Sentinel lymph node biopsy is a prognostic measure in pediatric melanoma.

Kim J, Sun Z, Gulack BC, Adam MA, Mosca PJ, Rice HE, Tracy ET.

J Pediatr Surg. 2016 Jun;51(6):986-90. doi: 10.1016/j.jpedsurg.2016.02.067. Epub 2016 Mar 4.

20.

Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy.

Brys AK, Gowda R, Loriaux DB, Robertson GP, Mosca PJ.

Biotechnol Adv. 2016 Sep-Oct;34(5):565-577. doi: 10.1016/j.biotechadv.2016.01.004. Epub 2016 Jan 28. Review.

PMID:
26826558
21.

A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer.

Whitley MJ, Cardona DM, Lazarides AL, Spasojevic I, Ferrer JM, Cahill J, Lee CL, Snuderl M, Blazer DG 3rd, Hwang ES, Greenup RA, Mosca PJ, Mito JK, Cuneo KC, Larrier NA, O'Reilly EK, Riedel RF, Eward WC, Strasfeld DB, Fukumura D, Jain RK, Lee WD, Griffith LG, Bawendi MG, Kirsch DG, Brigman BE.

Sci Transl Med. 2016 Jan 6;8(320):320ra4. doi: 10.1126/scitranslmed.aad0293.

22.

Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma.

Brys AK, Bhatti L, Bashir MR, Jaffe TA, Beasley GM, Nath NS, Salama AK, Tyler DS, Mosca PJ.

Ann Surg Oncol. 2016 Apr;23(4):1090-5. doi: 10.1245/s10434-015-4972-7. Epub 2015 Nov 16.

PMID:
26572755
23.

Pump-probe imaging of pigmented cutaneous melanoma primary lesions gives insight into metastatic potential.

Robles FE, Deb S, Wilson JW, Gainey CS, Selim MA, Mosca PJ, Tyler DS, Fischer MC, Warren WS.

Biomed Opt Express. 2015 Aug 27;6(9):3631-45. doi: 10.1364/BOE.6.003631. eCollection 2015 Sep 1.

24.

Sentinel lymph node biopsy following a rotational flap.

Brys AK, Schneider MM, Selim MA, Mosca PJ.

BMJ Case Rep. 2015 Jul 14;2015. pii: bcr2015210762. doi: 10.1136/bcr-2015-210762.

25.

Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib.

Jiang X, Anderson HB, Guy CD, Mosca PJ, Riedel RF, Cardona DM.

Case Rep Oncol Med. 2015;2015:317493. doi: 10.1155/2015/317493. Epub 2015 Jan 28.

26.

A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.

Beasley GM, Speicher P, Augustine CK, Dolber PC, Peterson BL, Sharma K, Mosca PJ, Royal R, Ross M, Zager JS, Tyler DS.

Ann Surg Oncol. 2015 Jan;22(1):287-94. doi: 10.1245/s10434-014-3887-z. Epub 2014 Aug 22.

27.

Quality of life after isolated limb infusion for in-transit melanoma of the extremity.

Jiang BS, Speicher PJ, Thomas S, Mosca PJ, Abernethy AP, Tyler DS.

Ann Surg Oncol. 2015 May;22(5):1694-700. doi: 10.1245/s10434-014-3979-9. Epub 2014 Aug 14.

28.

Defining the learning curve for team-based laparoscopic pancreaticoduodenectomy.

Speicher PJ, Nussbaum DP, White RR, Zani S, Mosca PJ, Blazer DG 3rd, Clary BM, Pappas TN, Tyler DS, Perez A.

Ann Surg Oncol. 2014 Nov;21(12):4014-9. doi: 10.1245/s10434-014-3839-7. Epub 2014 Jun 13.

PMID:
24923222
29.

Two-day lymphoscintigraphic imaging for melanoma.

Oldan JD, James OG, Mosca PJ, Tyler DS, Borges-Neto S.

Nucl Med Commun. 2014 Aug;35(8):870-5. doi: 10.1097/MNM.0000000000000136.

PMID:
24781011
30.

Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma.

Jiang BS, Beasley GM, Speicher PJ, Mosca PJ, Morse MA, Hanks B, Salama A, Tyler DS.

Ann Surg Oncol. 2014 Aug;21(8):2525-31. doi: 10.1245/s10434-014-3671-0. Epub 2014 Apr 4.

31.

Hypoxia in melanoma: using optical spectroscopy and EF5 to assess tumor oxygenation before and during regional chemotherapy for melanoma.

Speicher PJ, Beasley GM, Jiang B, Lidsky ME, Palmer GM, Scarbrough PM, Mosca PJ, Dewhirst MW, Tyler DS.

Ann Surg Oncol. 2014 May;21(5):1435-40. doi: 10.1245/s10434-013-3222-0. Epub 2013 Aug 28.

32.

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

Dannull J, Haley NR, Archer G, Nair S, Boczkowski D, Harper M, De Rosa N, Pickett N, Mosca PJ, Burchette J, Selim MA, Mitchell DA, Sampson J, Tyler DS, Pruitt SK.

J Clin Invest. 2013 Jul;123(7):3135-45. doi: 10.1172/JCI67544. Epub 2013 Jun 24.

33.

Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion.

Shetty G, Beasley GM, Sparks S, Barfield M, Masoud M, Mosca PJ, Pruitt SK, Salama AK, Chan C, Tyler DS, Weinhold KJ.

Ann Surg Oncol. 2013 Apr;20(4):1128-35. doi: 10.1245/s10434-012-2785-5. Epub 2013 Mar 2.

34.

Circulating tumor cells in melanoma patients.

Clawson GA, Kimchi E, Patrick SD, Xin P, Harouaka R, Zheng S, Berg A, Schell T, Staveley-O'Carroll KF, Neves RI, Mosca PJ, Thiboutot D.

PLoS One. 2012;7(7):e41052. doi: 10.1371/journal.pone.0041052. Epub 2012 Jul 19.

35.

A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion.

Beasley GM, Sharma K, Wong J, Miller M, Turley RS, Lidsky M, Masoud M, Dewhirst MW, Mosca PJ, Zager JS, Tyler DS.

Cancer. 2012 Dec 15;118(24):6136-43. doi: 10.1002/cncr.27676. Epub 2012 Jun 6.

36.

The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.

Madhunapantula SV, Mosca PJ, Robertson GP.

Cancer Biol Ther. 2011 Dec 15;12(12):1032-49. doi: 10.4161/cbt.12.12.18442. Epub 2011 Dec 15. Review.

37.

When a chance to cut is not a chance to cure: a future for palliative surgery?

Mosca PJ, Blazer DG 3rd, Wheeler JL, Abernethy AP.

Ann Surg Oncol. 2011 Nov;18(12):3235-9. doi: 10.1245/s10434-011-1787-z.

PMID:
21584829
38.

Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression.

Mosca PJ, Robertson GP.

Cancer Biol Ther. 2011 Mar 15;11(6):581-3. Epub 2011 Mar 15. No abstract available.

PMID:
21282973
39.

Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.

Santillan AA, Delman KA, Beasley GM, Mosca PJ, Hochwald SN, Grobmyer SR, Andtbacka RH, Noyes RD, Kane JM, Ross MI, Tyler DS, Zager JS.

Ann Surg Oncol. 2009 Sep;16(9):2570-8. doi: 10.1245/s10434-009-0563-9. Epub 2009 Jun 19.

PMID:
19543771
40.

A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.

Beasley GM, Caudle A, Petersen RP, McMahon NS, Padussis J, Mosca PJ, Zager JS, Hochwald SN, Grobmyer SR, Delman KA, Andtbacka RH, Noyes RD, Kane JM, Seigler H, Pruitt SK, Ross MI, Tyler DS.

J Am Coll Surg. 2009 May;208(5):706-15; discussion 715-7. doi: 10.1016/j.jamcollsurg.2008.12.019. Epub 2009 Mar 26.

PMID:
19476821
41.

Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI.

Padussis JC, Steerman SN, Tyler DS, Mosca PJ.

Int J Hyperthermia. 2008 May;24(3):239-49. doi: 10.1080/02656730701816410. Review.

PMID:
18393002
42.

Can surgeons improve survival in stage IV melanoma?

Mosca PJ, Teicher E, Nair SP, Pockaj BA.

J Surg Oncol. 2008 Apr 1;97(5):462-8. doi: 10.1002/jso.20950. Review.

PMID:
18270974
43.

Current immunotherapeutic strategies in malignant melanoma.

Agostino NM, Ali A, Nair SG, Mosca PJ.

Surg Oncol Clin N Am. 2007 Oct;16(4):945-73, xi. Review.

PMID:
18022553
44.

Dendritic cell vaccines.

Mosca PJ, Lyerly HK, Clay TM, Morse MA, Lyerly HK.

Front Biosci. 2007 May 1;12:4050-60. Review.

PMID:
17485358
45.

Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma.

Posther KE, Selim MA, Mosca PJ, Stanley WE, Johnson JL, Tyler DS, Seigler HF.

Ann Surg Oncol. 2006 May;13(5):728-39. Epub 2006 Mar 17.

PMID:
16538415
46.

Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response.

Aloia TA, Grubbs E, Onaitis M, Mosca PJ, Cheng TY, Seigler H, Tyler DS.

Arch Surg. 2005 Nov;140(11):1115-20.

PMID:
16301451
47.

Immune monitoring.

Mosca PJ, Clay TM, Morse MA, Lyerly HK.

Cancer Treat Res. 2005;123:369-88. Review.

PMID:
16211879
48.

Pneumatosis intestinalis after lung transplant.

Ho LM, Mosca PJ, Thompson WM.

Abdom Imaging. 2005 Sep-Oct;30(5):598-600. Epub 2005 Aug 11.

PMID:
16096869
49.

Melanoma arising in a skin graft.

Hall JG, Herman C, Cook JL, Tyler D, Seigler HF, Mosca PJ.

Ann Plast Surg. 2005 Jan;54(1):92-6.

PMID:
15613891
50.

Surgical management of cutaneous melanoma: current practice and impact on prognosis.

Mosca PJ, Tyler DS, Seigler HF.

Adv Surg. 2004;38:85-119. Review. No abstract available.

PMID:
15515616

Supplemental Content

Loading ...
Support Center